Onco Wiki / Regimen

Etoposide-platinum + concurrent thoracic RT (limited SCLC)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

ComponentsDRUG-CISPLATIN DRUG-ETOPOSIDE
IDREG-EP-CONCURRENT-RT-SCLC-LIMITED
TypeRegimen
Statuspending_clinical_signoff
DiseasesNone declared
SourcesSRC-ESMO-SCLC-2021 SRC-NCCN-SCLC-2025

Notes

CONVERT: once-daily 60 Gy non-inferior to BID 45 Gy. Concurrent (not sequential) chemo+RT improves outcomes. PCI consideration for CR/PR patients post-CRT.

Used By

Indication